Search for Clinical Trial Results
Hemophilia A - 41 Studies Found
Status | Study |
Completed |
Study Name: Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A Condition: Hemophilia A Date: 2005-08-30 Interventions:
|
Completed |
Study Name: Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment Condition: Hemophilia A Date: 2008-02-04 Interventions:
|
Active, not recruiting |
Study Name: A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A Condition: Hemophilia A Date: 2012-03-28 Interventions: Biological: BAY94-9027 Intravenous infusion of BAY94-9027 |
Recruiting |
Study Name: Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." Condition: Hemophilia A Date: 2015-10-20 Interventions:
|
Completed |
Study Name: Study of Biostate® in Children With Hemophilia A Condition: Hemophilia A Date: 2010-10-01 Interventions: Biological: Biostate 1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day |
Completed |
Study Name: Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery Condition: Hemophilia A Date: 2006-07-25 Interventions:
|
Completed |
Study Name: Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery Condition: Hemophilia A Date: 2005-10-20 Interventions: Biological: ReFacto AF |
Recruiting |
Study Name: A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Condition: Hemophilia A Date: 2016-07-26 Interventions: Drug: Emicizumab Participants will receive emicizumab prophylaxis at the specified dose subcutaneously u |
Completed |
Study Name: Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A Condition: Hemophilia A Date: 2012-03-22 Interventions: Drug: GreenGene Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus |
Enrolling by invitation |
Study Name: Platelet Function in Patients With Hemophilia A Condition: Hemophilia A Date: 2014-03-19 |